Inhibrx, Inc. (NASDAQ:INBX) CEO Acquires $316,200.00 in Stock

Inhibrx, Inc. (NASDAQ:INBX) CEO Mark Lappe bought 20,000 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were acquired at an average cost of $15.81 per share, with a total value of $316,200.00. Following the completion of the transaction, the chief executive officer now owns 165,000 shares of the company’s stock, valued at $2,608,650. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

Mark Lappe also recently made the following trade(s):

• On Thursday, August 29th, Mark Lappe bought 10,000 shares of Inhibrx stock. The shares were acquired at an average cost of $14.03 per share, with a total value of $140,300.00.

Inhibrx Stock Up 0.6 %

Shares of INBX stock opened at $16.04 on Thursday. Inhibrx, Inc. has a 52-week low of $10.80 and a 52-week high of $18.95. The company has a 50-day simple moving average of $13.38 and a two-hundred day simple moving average of $24.96.

Inhibrx (NASDAQ:INBX) last issued its quarterly earnings data on Tuesday, August 13th. The company reported $125.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.60) by $129.08. The firm had revenue of $0.10 million during the quarter. Equities research analysts predict that Inhibrx, Inc. will post 87.5 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vestal Point Capital LP bought a new position in shares of Inhibrx during the 4th quarter valued at approximately $58,140,000. PFM Health Sciences LP grew its position in shares of Inhibrx by 86.4% during the 4th quarter. PFM Health Sciences LP now owns 537,964 shares of the company’s stock valued at $20,443,000 after acquiring an additional 249,347 shares during the period. MMCAP International Inc. SPC bought a new position in shares of Inhibrx during the 1st quarter valued at approximately $15,782,000. Charles Schwab Investment Management Inc. grew its position in shares of Inhibrx by 8.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 229,866 shares of the company’s stock valued at $8,735,000 after acquiring an additional 17,762 shares during the period. Finally, Swiss National Bank grew its position in shares of Inhibrx by 8.5% during the 1st quarter. Swiss National Bank now owns 42,000 shares of the company’s stock valued at $1,468,000 after acquiring an additional 3,300 shares during the period. 82.46% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, JMP Securities started coverage on shares of Inhibrx in a research report on Tuesday, July 23rd. They issued a “market perform” rating for the company.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.